24912431	142	Cao Y	The WHIM-like CXCR4(S338X) somatic mutation activates AKT and ERK, and promotes resistance to ibrutinib and other agents used in the treatment of Waldenstrom's Macroglobulinemia.	Leukemia	2015	15
163658	189	Lozzio CB	Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome.	Blood	1975	462
16397263	207	Schittenhelm MM	Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies.	Cancer research	2006	92
17611497	207	Carpten JD	A transforming mutation in the pleckstrin homology domain of AKT1 in cancer.	Nature	2007	373
18337767	207	Steelman LS	Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia.	Leukemia	2008	94
18414037	207	Palomero T	The role of the PTEN/AKT Pathway in NOTCH1-induced leukemia.	Cell cycle	2008	65
18504432	207	Bleeker FE	AKT1(E17K) in human solid tumours.	Oncogene	2008	55
25541152	207	Musilova K	MicroRNAs in B-cell lymphomas: how a complex biology gets more complex.	Leukemia	2015	32
17968022	472	Austen B	Mutation status of the residual ATM allele is an important determinant of the cellular response to chemotherapy and survival in patients with chronic lymphocytic leukemia containing an 11q deletion.	Journal of clinical oncology 	2007	59
23091097	472	Skowronska A	Biallelic ATM inactivation significantly reduces survival in patients treated on the United Kingdom Leukemia Research Fund Chronic Lymphocytic Leukemia 4 trial.	Journal of clinical oncology 	2012	32
19070581	595	Tsai AG	Human chromosomal translocations at CpG sites and a theoretical basis for their lineage and stage specificity.	Cell	2008	78
2875799	596	Cleary ML	Cloning and structural analysis of cDNAs for bcl-2 and a hybrid bcl-2/immunoglobulin transcript resulting from the t(14;18) translocation.	Cell	1986	211
3874430	596	Tsujimoto Y	Involvement of the bcl-2 gene in human follicular lymphoma.	Science	1985	237
23471820	596	Sanda T	TYK2-STAT1-BCL2 pathway dependence in T-cell acute lymphoblastic leukemia.	Cancer discovery	2013	30
27069256	596	Anderson MA	The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism.	Blood	2016	15
27178240	596	Stilgenbauer S	Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study.	The Lancet. Oncology	2016	29
21663470	673	Tiacci E	BRAF mutations in hairy-cell leukemia.	The New England journal of medicine	2011	157
21422473	695	Herman SE	Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765.	Blood	2011	169
24869598	695	Woyach JA	Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib.	The New England journal of medicine	2014	142
25150798	695	Burger JA	Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study.	The Lancet. Oncology	2014	56
25189416	695	Cheng S	Functional characterization of BTK(C481S) mutation that confers ibrutinib resistance: exploration of alternative kinase inhibitors.	Leukemia	2015	20
26641137	695	Byrd JC	Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia.	The New England journal of medicine	2016	43
24325356	811	Klampfl T	Somatic mutations of calreticulin in myeloproliferative neoplasms.	The New England journal of medicine	2013	259
24325359	811	Nangalia J	Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2.	The New England journal of medicine	2013	240
26449662	811	Pietra D	Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms.	Leukemia	2016	14
1720541	861	Miyoshi H	t(8;21) breakpoints on chromosome 21 in acute myeloid leukemia are clustered within a limited region of a single gene, AML1.	Proceedings of the National Academy of Sciences of the United States of America	1991	163
19808697	861	Tang JL	AML1/RUNX1 mutations in 470 adult patients with de novo acute myeloid leukemia: prognostic implication and interaction with other gene alterations.	Blood	2009	60
21343560	861	Gaidzik VI	RUNX1 mutations in acute myeloid leukemia: results from a comprehensive genetic and clinical analysis from the AML study group.	Journal of clinical oncology 	2011	53
22201794	861	Lam K	RUNX1 and RUNX1-ETO: roles in hematopoiesis and leukemogenesis.	Frontiers in bioscience	2012	33
22753902	861	Mendler JH	RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and MicroRNA expression signatures.	Journal of clinical oncology 	2012	46
23352661	861	Wilkinson AC	RUNX1 is a key target in t(4;11) leukemias that contributes to gene activation through an AF4-MLL complex interaction.	Cell reports	2013	35
24055056	861	Ben-Ami O	Addiction of t(8;21) and inv(16) acute myeloid leukemia to native RUNX1.	Cell reports	2013	26
19074904	867	Dunbar AJ	250K single nucleotide polymorphism array karyotyping identifies acquired uniparental disomy and homozygous mutations, including novel missense substitutions of c-Cbl, in myeloid malignancies.	Cancer research	2008	89
19387008	867	Grand FH	Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms.	Blood	2009	111
19571318	867	Loh ML	Mutations in CBL occur frequently in juvenile myelomonocytic leukemia.	Blood	2009	66
19901108	867	Makishima H	Mutations of e3 ubiquitin ligase cbl family members constitute a novel common pathogenic lesion in myeloid malignancies.	Journal of clinical oncology 	2009	59
20694012	867	Niemeyer CM	Germline CBL mutations cause developmental abnormalities and predispose to juvenile myelomonocytic leukemia.	Nature genetics	2010	65
21886171	947	Platzbecker U	Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial.	Leukemia	2012	42
24550281	947	Corces-Zimmerman MR	Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission.	Proceedings of the National Academy of Sciences of the United States of America	2014	106
7958916	1026	Di Leonardo A	DNA damage triggers a prolonged p53-dependent G1 arrest and long-term induction of Cip1 in normal human fibroblasts.	Genes and development	1994	207
17890455	1029	Kawamata N	Molecular allelokaryotyping of pediatric acute lymphoblastic leukemias by high-resolution single nucleotide polymorphism oligonucleotide genomic microarray.	Blood	2008	57
18688285	1029	Hacein-Bey-Abina S	Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1.	The Journal of clinical investigation	2008	456
18688286	1029	Howe SJ	Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients.	The Journal of clinical investigation	2008	321
21248843	1029	Notta F	Evolution of human BCR-ABL1 lymphoblastic leukaemia-initiating cells.	Nature	2011	154
21509761	1029	Ahn JB	DNA methylation predicts recurrence from resected stage III proximal colon cancer.	Cancer	2011	47
24127483	1029	Fabbri G	Genetic lesions associated with chronic lymphocytic leukemia transformation to Richter syndrome.	The Journal of experimental medicine	2013	26
24957142	1029	Moorman AV	A novel integrated cytogenetic and genomic classification refines risk stratification in pediatric acute lymphoblastic leukemia.	Blood	2014	24
16707479	1030	Yang AS	DNA methylation changes after 5-aza-2'-deoxycytidine therapy in patients with leukemia.	Cancer research	2006	76
22493413	1043	Pettitt AR	Alemtuzumab in combination with methylprednisolone is a highly effective induction regimen for patients with chronic lymphocytic leukemia and deletion of TP53: final results of the national cancer research institute CLL206 trial.	Journal of clinical oncology 	2012	31
11242107	1050	Pabst T	Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-alpha (C/EBPalpha), in acute myeloid leukemia.	Nature genetics	2001	172
11283671	1050	Pabst T	AML1-ETO downregulates the granulocytic differentiation factor C/EBPalpha in t(8;21) myeloid leukemia.	Nature medicine	2001	99
14726504	1050	Fröhling S	CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: prognostic relevance and analysis of cooperating mutations.	Journal of clinical oncology 	2004	80
15084694	1050	Valk PJ	Prognostically useful gene-expression profiles in acute myeloid leukemia.	The New England journal of medicine	2004	309
16051734	1050	Döhner K	Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations.	Blood	2005	140
16076867	1050	Schnittger S	Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype.	Blood	2005	106
16109776	1050	Verhaak RG	Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance.	Blood	2005	94
16446383	1050	Radomska HS	Block of C/EBP alpha function by phosphorylation in acute myeloid leukemia with FLT3 activating mutations.	The Journal of experimental medicine	2006	63
16960150	1050	Mrózek K	Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification?	Blood	2007	122
18288131	1050	Renneville A	Cooperating gene mutations in acute myeloid leukemia: a review of the literature.	Leukemia	2008	62
18450602	1050	Schlenk RF	Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.	The New England journal of medicine	2008	304
18559874	1050	Paschka P	Wilms' tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study.	Journal of clinical oncology 	2008	60
18809607	1050	Marcucci G	Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: a Cancer and Leukemia Group B Study.	Journal of clinical oncology 	2008	108
19075268	1050	Koschmieder S	Dysregulation of the C/EBPalpha differentiation pathway in human cancer.	Journal of clinical oncology 	2009	45
20038735	1050	Dufour A	Acute myeloid leukemia with biallelic CEBPA gene mutations and normal karyotype represents a distinct genetic entity associated with a favorable clinical outcome.	Journal of clinical oncology 	2010	45
20368538	1050	Wagner K	Impact of IDH1 R132 mutations and an IDH1 single nucleotide polymorphism in cytogenetically normal acute myeloid leukemia: SNP rs11554137 is an adverse prognostic factor.	Journal of clinical oncology 	2010	55
20889924	1050	Pulikkan JA	C/EBPα regulated microRNA-34a targets E2F3 during granulopoiesis and is down-regulated in AML with CEBPA mutations.	Blood	2010	45
21177436	1050	Taskesen E	Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: further evidence for CEBPA double mutant AML as a distinctive disease entity.	Blood	2011	47
21881046	1050	Shen Y	Gene mutation patterns and their prognostic impact in a cohort of 1185 patients with acute myeloid leukemia.	Blood	2011	63
22180162	1050	Estey EH	Acute myeloid leukemia: 2012 update on diagnosis, risk stratification, and management.	American journal of hematology	2012	36
22417203	1050	Patel JP	Prognostic relevance of integrated genetic profiling in acute myeloid leukemia.	The New England journal of medicine	2012	352
23526416	1050	Estey EH	Acute myeloid leukemia: 2013 update on risk-stratification and management.	American journal of hematology	2013	65
24183681	1050	Zhang H	Sox4 is a key oncogenic target in C/EBPα mutant acute myeloid leukemia.	Cancer cell	2013	31
24487413	1050	Kihara R	Comprehensive analysis of genetic alterations and their prognostic impacts in adult acute myeloid leukemia patients.	Leukemia	2014	34
25079101	1050	Meyer SC	Translational implications of somatic genomics in acute myeloid leukaemia.	The Lancet. Oncology	2014	21
25512507	1050	Garzon R	Expression and prognostic impact of lncRNAs in acute myeloid leukemia.	Proceedings of the National Academy of Sciences of the United States of America	2014	35
23535063	1378	Zhu HH	MRD-directed risk stratification treatment may improve outcomes of t(8;21) AML in the first complete remission: results from the AML05 multicenter trial.	Blood	2013	26
25239228	1378	Chen YB	Phase I trial of maintenance sorafenib after allogeneic hematopoietic stem cell transplantation for fms-like tyrosine kinase 3 internal tandem duplication acute myeloid leukemia.	Biology of blood and marrow transplantation 	2014	25
16155604	1385	Grassmann R	Molecular mechanisms of cellular transformation by HTLV-1 Tax.	Oncogene	2005	143
21390130	1387	Mullighan CG	CREBBP mutations in relapsed acute lymphoblastic leukaemia.	Nature	2011	162
22941188	1387	Peifer M	Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer.	Nature genetics	2012	215
24662245	1387	Mar BG	Mutations in epigenetic regulators including SETD2 are gained during relapse in paediatric acute lymphoblastic leukaemia.	Nature communications	2014	35
25713363	1387	Green MR	Mutations in early follicular lymphoma progenitors are associated with suppressed antigen presentation.	Proceedings of the National Academy of Sciences of the United States of America	2015	33
16365288	1441	Lu X	Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation.	Proceedings of the National Academy of Sciences of the United States of America	2005	90
23656643	1441	Maxson JE	Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML.	The New England journal of medicine	2013	77
23896413	1441	Gotlib J	The new genetics of chronic neutrophilic leukemia and atypical CML: implications for diagnosis and treatment.	Blood	2013	31
24441292	1441	Tefferi A	An overview on CALR and CSF3R mutations and a proposal for revision of WHO diagnostic criteria for myeloproliferative neoplasms.	Leukemia	2014	41
21067377	1788	Ley TJ	DNMT3A mutations in acute myeloid leukemia.	The New England journal of medicine	2010	433
21415852	1788	Walter MJ	Recurrent DNMT3A mutations in patients with myelodysplastic syndromes.	Leukemia	2011	136
21670448	1788	Thol F	Incidence and prognostic influence of DNMT3A mutations in acute myeloid leukemia.	Journal of clinical oncology 	2011	77
21828135	1788	Jankowska AM	Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A.	Blood	2011	80
22077061	1788	Hou HA	DNMT3A mutations in acute myeloid leukemia: stability during disease evolution and clinical implications.	Blood	2012	42
22291079	1788	Marcucci G	Age-related prognostic impact of different types of DNMT3A mutations in adults with primary cytogenetically normal acute myeloid leukemia.	Journal of clinical oncology 	2012	65
22490330	1788	Ribeiro AF	Mutant DNMT3A: a marker of poor prognosis in acute myeloid leukemia.	Blood	2012	62
23341344	1788	Grossmann V	The molecular profile of adult T-cell acute lymphoblastic leukemia: mutations in RUNX1 and DNMT3A are associated with poor prognosis in T-ALL.	Genes, chromosomes and cancer	2013	31
23603912	1788	Neumann M	Whole-exome sequencing in adult ETP-ALL reveals a high rate of DNMT3A mutations.	Blood	2013	45
23632886	1788	Gaidzik VI	Clinical impact of DNMT3A mutations in younger adult patients with acute myeloid leukemia: results of the AML Study Group (AMLSG).	Blood	2013	31
23704090	1788	Krönke J	Clonal evolution in relapsed NPM1-mutated acute myeloid leukemia.	Blood	2013	42
24142997	1788	Luthra R	Next-generation sequencing-based multigene mutational screening for acute myeloid leukemia using MiSeq: applicability for diagnostics and disease monitoring.	Haematologica	2014	30
24522528	1788	Shlush LI	Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia.	Nature	2014	220
24614070	1788	Tatton-Brown K	Mutations in the DNA methyltransferase gene DNMT3A cause an overgrowth syndrome with intellectual disability.	Nature genetics	2014	36
24699305	1788	Im AP	DNMT3A and IDH mutations in acute myeloid leukemia and other myeloid malignancies: associations with prognosis and potential treatment strategies.	Leukemia	2014	37
25693834	1788	Yang L	DNMT3A in haematological malignancies.	Nature reviews. Cancer	2015	43
17126425	1956	McCubrey JA	Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance.	Biochimica et biophysica acta	2007	423
20864632	1956	Attolini CS	A mathematical framework to determine the temporal sequence of somatic genetic events in cancer.	Proceedings of the National Academy of Sciences of the United States of America	2010	47
23695894	2056	Tefferi A	Polycythemia vera and essential thrombocythemia: 2013 update on diagnosis, risk-stratification, and management.	American journal of hematology	2013	29
25611051	2056	Tefferi A	Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management.	American journal of hematology	2015	22
9360930	2120	Lacronique V	A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia.	Science	1997	164
10602411	2120	van Dongen JJ	Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: investigation of minimal residual disease in acute leukemia.	Leukemia	1999	111
12048236	2120	Mori H	Chromosome translocations and covert leukemic clones are generated during normal fetal development.	Proceedings of the National Academy of Sciences of the United States of America	2002	93
15908956	2120	Castor A	Distinct patterns of hematopoietic stem cell involvement in acute lymphoblastic leukemia.	Nature medicine	2005	67
18202291	2120	Hong D	Initiating and cancer-propagating cells in TEL-AML1-associated childhood leukemia.	Science	2008	94
20409752	2120	Moorman AV	Prognostic effect of chromosomal abnormalities in childhood B-cell precursor acute lymphoblastic leukaemia: results from the UK Medical Research Council ALL97/99 randomised trial.	The Lancet. Oncology	2010	58
22162831	2120	Van Vlierberghe P	ETV6 mutations in early immature human T cell leukemias.	The Journal of experimental medicine	2011	49
22578774	2120	De Braekeleer E	ETV6 fusion genes in hematological malignancies: a review.	Leukemia research	2012	38
18272813	2122	Lugthart S	High EVI1 levels predict adverse outcome in acute myeloid leukemia: prevalence of EVI1 overexpression and chromosome 3q26 abnormalities underestimated.	Blood	2008	55
25295500	2122	Hacein-Bey-Abina S	A modified γ-retrovirus vector for X-linked severe combined immunodeficiency.	The New England journal of medicine	2014	48
21921040	2146	Guglielmelli P	EZH2 mutational status predicts poor survival in myelofibrosis.	Blood	2011	41
25965569	2146	Kim E	SRSF2 Mutations Contribute to Myelodysplasia by Mutant-Specific Effects on Exon Recognition.	Cancer cell	2015	49
11377686	2187	Valent P	Diagnostic criteria and classification of mastocytosis: a consensus proposal.	Leukemia research	2001	110
10216104	2322	Kiyoi H	Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia.	Blood	1999	104
10698507	2322	Hayakawa F	Tandem-duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines.	Oncogene	2000	92
11290608	2322	Yamamoto Y	Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies.	Blood	2001	189
11535508	2322	Kottaridis PD	The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials.	Blood	2001	208
11585760	2322	Whitman SP	Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a cancer and leukemia group B study.	Cancer research	2001	113
12036858	2322	Thiede C	Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis.	Blood	2002	279
12070009	2322	Schnittger S	Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease.	Blood	2002	141
12194988	2322	Kelly LM	Genetics of myeloid leukemias.	Annual review of genomics and human genetics	2002	97
12393388	2322	Fröhling S	Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm.	Blood	2002	135
12531805	2322	O'Farrell AM	SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo.	Blood	2003	164
14759363	2322	Griffith J	The structural basis for autoinhibition of FLT3 by the juxtamembrane domain.	Molecular cell	2004	94
15345597	2322	Stone RM	Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412.	Blood	2005	132
15459012	2322	Fiedler W	A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease.	Blood	2005	80
15514006	2322	George P	Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3.	Blood	2005	74
16150941	2322	Heidel F	Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domain.	Blood	2006	63
16857985	2322	Knapper S	A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy.	Blood	2006	96
16912228	2322	Meshinchi S	Clinical implications of FLT3 mutations in pediatric AML.	Blood	2006	74
17124058	2322	Small D	FLT3 mutations: biology and treatment.	Hematology. American Society of Hematology. Education Program	2006	60
17940205	2322	Whitman SP	FLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplications.	Blood	2008	68
17957027	2322	Gale RE	The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia.	Blood	2008	108
18187662	2322	Garzon R	MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia.	Blood	2008	196
18192505	2322	Sallmyr A	Internal tandem duplication of FLT3 (FLT3/ITD) induces increased ROS production, DNA damage, and misrepair: implications for poor prognosis in AML.	Blood	2008	71
18270328	2322	Tomasson MH	Somatic mutations and germline sequence variants in the expressed tyrosine kinase genes of patients with de novo acute myeloid leukemia.	Blood	2008	67
18450603	2322	Marcucci G	MicroRNA expression in cytogenetically normal acute myeloid leukemia.	The New England journal of medicine	2008	142
19029442	2322	Pratz KW	A pharmacodynamic study of the FLT3 inhibitor KW-2449 yields insight into the basis for clinical response.	Blood	2009	52
19047294	2322	Büchner T	Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: a study by the German Acute Myeloid Leukemia Cooperative Group.	Journal of clinical oncology 	2009	49
19549778	2322	Meshinchi S	Structural and functional alterations of FLT3 in acute myeloid leukemia.	Clinical cancer research 	2009	51
20007803	2322	Pratz KW	FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML.	Blood	2010	75
20212254	2322	Ravandi F	Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia.	Journal of clinical oncology 	2010	94
20656931	2322	Whitman SP	FLT3 internal tandem duplication associates with adverse outcome and gene- and microRNA-expression signatures in patients 60 years of age or older with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.	Blood	2010	58
20733134	2322	Fischer T	Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3.	Journal of clinical oncology 	2010	89
20952518	2322	Borthakur G	Phase I study of sorafenib in patients with refractory or relapsed acute leukemias.	Haematologica	2011	45
21127174	2322	Kayser S	The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML.	Blood	2011	45
21148331	2322	Schnittger S	RUNX1 mutations are frequent in de novo AML with noncomplex karyotype and confer an unfavorable prognosis.	Blood	2011	42
22291086	2322	Brunet S	Impact of FLT3 internal tandem duplication on the outcome of related and unrelated hematopoietic transplantation for adult acute myeloid leukemia in first remission: a retrospective analysis.	Journal of clinical oncology 	2012	39
22368270	2322	Man CH	Sorafenib treatment of FLT3-ITD(+) acute myeloid leukemia: favorable initial outcome and mechanisms of subsequent nonresponsiveness associated with the emergence of a D835 mutation.	Blood	2012	59
22504184	2322	Smith CC	Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia.	Nature	2012	146
22614177	2322	Swords R	Targeting the FMS-like tyrosine kinase 3 in acute myeloid leukemia.	Leukemia	2012	37
22627678	2322	Stone RM	Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia.	Leukemia	2012	47
22715121	2322	Iland HJ	All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4).	Blood	2012	34
23071272	2322	Quintás-Cardama A	Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia.	Blood	2012	32
23087056	2322	Tyner JW	Kinase pathway dependence in primary human leukemias determined by rapid inhibitor screening.	Cancer research	2013	45
23321257	2322	Jourdan E	Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia.	Blood	2013	32
23377436	2322	Pratcorona M	Favorable outcome of patients with acute myeloid leukemia harboring a low-allelic burden FLT3-ITD mutation and concomitant NPM1 mutation: relevance to post-remission therapy.	Blood	2013	29
23430109	2322	Smith CC	Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD.	Blood	2013	30
23613521	2322	Ravandi F	Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation.	Blood	2013	58
23631653	2322	Kayser S	FLT3 tyrosine kinase inhibitors in acute myeloid leukemia: clinical implications and limitations.	Leukemia and lymphoma	2014	28
23897964	2322	Serve H	Sorafenib in combination with intensive chemotherapy in elderly patients with acute myeloid leukemia: results from a randomized, placebo-controlled trial.	Journal of clinical oncology 	2013	51
24002496	2322	Cortes JE	Phase I study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMS-like tyrosine kinase 3-internal tandem duplication status.	Journal of clinical oncology 	2013	56
24227820	2322	Galanis A	Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutants.	Blood	2014	32
24319184	2322	Levis M	FLT3 mutations in acute myeloid leukemia: what is the best approach in 2013?	Hematology. American Society of Hematology. Education Program	2013	30
25092144	2322	Gerloff D	NF-κB/STAT5/miR-155 network targets PU.1 in FLT3-ITD-driven acute myeloid leukemia.	Leukemia	2015	18
25231999	2322	Konig H	Targeting FLT3 to treat leukemia.	Expert opinion on therapeutic targets	2015	20
25253770	2322	Irving J	Ras pathway mutations are prevalent in relapsed childhood acute lymphoblastic leukemia and confer sensitivity to MEK inhibition.	Blood	2014	39
25270908	2322	Schlenk RF	Differential impact of allelic ratio and insertion site in FLT3-ITD-positive AML with respect to allogeneic transplantation.	Blood	2014	26
25280219	2322	Li L	SIRT1 activation by a c-MYC oncogenic network promotes the maintenance and drug resistance of human FLT3-ITD acute myeloid leukemia stem cells.	Cell stem cell	2014	22
12172547	2623	Wechsler J	Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome.	Nature genetics	2002	152
15659348	2623	Crispino JD	GATA1 in normal and malignant hematopoiesis.	Seminars in cell and developmental biology	2005	71
24952648	2623	Ludwig LS	Altered translation of GATA1 in Diamond-Blackfan anemia.	Nature medicine	2014	47
21670465	2624	Hsu AP	Mutations in GATA2 are associated with the autosomal dominant and sporadic monocytopenia and mycobacterial infection (MonoMAC) syndrome.	Blood	2011	109
21765025	2624	Dickinson RE	Exome sequencing identifies GATA-2 mutation as the cause of dendritic cell, monocyte, B and NK lymphoid deficiency.	Blood	2011	81
22147895	2624	Kazenwadel J	Loss-of-function germline GATA2 mutations in patients with MDS/AML or MonoMAC syndrome and primary lymphedema reveal a key role for GATA2 in the lymphatic vasculature.	Blood	2012	58
23223431	2624	Pasquet M	High frequency of GATA2 mutations in patients with mild chronic neutropenia evolving to MonoMac syndrome, myelodysplasia, and acute myeloid leukemia.	Blood	2013	44
24227816	2624	Spinner MA	GATA2 deficiency: a protean disorder of hematopoiesis, lymphatics, and immunity.	Blood	2014	79
24345756	2624	Dickinson RE	The evolution of cellular deficiency in GATA2 mutation.	Blood	2014	40
26607380	2624	Mazumdar C	Leukemia-Associated Cohesin Mutants Dominantly Enforce Stem Cell Programs and Impair Human Hematopoietic Progenitor Differentiation.	Cell stem cell	2015	21
2547513	3265	Bos JL	ras oncogenes in human cancer: a review.	Cancer research	1989	956
19657110	3417	Mardis ER	Recurring mutations found by sequencing an acute myeloid leukemia genome.	The New England journal of medicine	2009	605
20097881	3417	Chou WC	Distinct clinical and biologic characteristics in adult acute myeloid leukemia bearing the isocitrate dehydrogenase 1 mutation.	Blood	2010	56
20142433	3417	Gross S	Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations.	The Journal of experimental medicine	2010	183
20171147	3417	Ward PS	The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate.	Cancer cell	2010	426
20368543	3417	Marcucci G	IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.	Journal of clinical oncology 	2010	179
20410924	3417	Pardanani A	IDH1 and IDH2 mutation analysis in chronic- and blast-phase myeloproliferative neoplasms.	Leukemia	2010	41
20508616	3417	Tefferi A	IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis.	Leukemia	2010	72
20567020	3417	Paschka P	IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication.	Journal of clinical oncology 	2010	152
20625116	3417	Boissel N	Prognostic impact of isocitrate dehydrogenase enzyme isoforms 1 and 2 mutations in acute myeloid leukemia: a study by the Acute Leukemia French Association group.	Journal of clinical oncology 	2010	45
20805365	3417	Schnittger S	IDH1 mutations are detected in 6.6% of 1414 AML patients and are associated with intermediate risk karyotype and unfavorable prognosis in adults younger than 60 years and unmutated NPM1 status.	Blood	2010	41
21130701	3417	Figueroa ME	Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation.	Cancer cell	2010	586
21598255	3417	Amary MF	IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours.	The Journal of pathology	2011	161
22899282	3417	Duncan CG	A heterozygous IDH1R132H/WT mutation induces genome-wide alterations in DNA methylation.	Genome research	2012	48
23558173	3417	Wang F	Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation.	Science	2013	152
23641016	3417	DiNardo CD	Serum 2-hydroxyglutarate levels predict isocitrate dehydrogenase mutations and clinical outcome in acute myeloid leukemia.	Blood	2013	35
23954893	3417	Chaturvedi A	Mutant IDH1 promotes leukemogenesis in vivo and can be specifically targeted in human AML.	Blood	2013	43
24333121	3417	Emadi A	Inhibition of glutaminase selectively suppresses the growth of primary acute myeloid leukemia cells with IDH mutations.	Experimental hematology	2014	32
25599133	3417	Chan SM	Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia.	Nature medicine	2015	41
27005468	3417	Dang L	IDH mutations in cancer and progress toward development of targeted therapeutics.	Annals of oncology 	2016	16
21596855	3418	Green CL	The prognostic significance of IDH2 mutations in AML depends on the location of the mutation.	Blood	2011	47
27276561	3418	Papaemmanuil E	Genomic Classification and Prognosis in Acute Myeloid Leukemia.	The New England journal of medicine	2016	79
10784449	3561	Cavazzana-Calvo M	Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease.	Science	2000	381
11961146	3561	Hacein-Bey-Abina S	Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy.	The New England journal of medicine	2002	184
14564000	3561	Hacein-Bey-Abina S	LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1.	Science	2003	831
15610804	3561	Gaspar HB	Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gammaretroviral vector.	Lancet	2004	156
20228274	3561	Wang GP	Dynamics of gene-modified progenitor cells analyzed by tracking retroviral integration sites in a human SCID-X1 gene therapy trial.	Blood	2010	47
23566838	3561	Mukherjee S	Gene therapy for PIDs: progress, pitfalls and prospects.	Gene	2013	36
18559588	3716	Jeong EG	Somatic mutations of JAK1 and JAK3 in acute leukemias and solid cancers.	Clinical cancer research 	2008	55
19470474	3716	Mullighan CG	JAK mutations in high-risk childhood acute lymphoblastic leukemia.	Proceedings of the National Academy of Sciences of the United States of America	2009	148
23406773	3716	Quintás-Cardama A	Molecular pathways: Jak/STAT pathway: mutations, inhibitors, and resistance.	Clinical cancer research 	2013	59
15793561	3717	James C	A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera.	Nature	2005	653
15858187	3717	Kralovics R	A gain-of-function mutation of JAK2 in myeloproliferative disorders.	The New England journal of medicine	2005	669
15860661	3717	Steensma DP	The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes.	Blood	2005	76
15920007	3717	Jones AV	Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders.	Blood	2005	152
16037387	3717	Jelinek J	JAK2 mutation 1849G&amp;gt;T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia.	Blood	2005	73
16081687	3717	Levine RL	The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia.	Blood	2005	77
16325696	3717	Campbell PJ	Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study.	Lancet	2005	83
17198871	3717	Nussenzveig RH	Polycythemia vera is not initiated by JAK2V617F mutation.	Experimental hematology	2007	69
17363731	3717	Theocharides A	Leukemic blasts in transformed JAK2-V617F-positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation.	Blood	2007	65
17564968	3717	Yamamoto G	Highly sensitive method for genomewide detection of allelic composition in nonpaired, primary tumor specimens by use of affymetrix single-nucleotide-polymorphism genotyping microarrays.	American journal of human genetics	2007	87
18496562	3717	Vannucchi AM	Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal.	Leukemia	2008	58
18779404	3717	Levine RL	Myeloproliferative disorders.	Blood	2008	93
18805579	3717	Bercovich D	Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndrome.	Lancet	2008	91
19474426	3717	Delhommeau F	Mutation in TET2 in myeloid cancers.	The New England journal of medicine	2009	411
19826111	3717	Quintás-Cardama A	Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera.	Journal of clinical oncology 	2009	59
19965641	3717	Hertzberg L	Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: a report from the International BFM Study Group.	Blood	2010	85
20008298	3717	Santos FP	Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis.	Blood	2010	61
20008300	3717	Beer PA	Two routes to leukemic transformation after a JAK2 mutation-positive myeloproliferative neoplasm.	Blood	2010	63
20631743	3717	Passamonti F	A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications.	Leukemia	2010	54
21151131	3717	Griffiths DS	LIF-independent JAK signalling to chromatin in embryonic stem cells uncovered from an adult stem cell disease.	Nature cell biology	2011	36
21283107	3717	Quintás-Cardama A	Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond.	Nature reviews. Drug discovery	2011	74
22869151	3717	Vainchenker W	JAK/STAT signaling in hematological malignancies.	Oncogene	2013	63
24371211	3717	Rotunno G	Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia.	Blood	2014	47
24402162	3717	Tefferi A	CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons.	Leukemia	2014	61
24478400	3717	Lundberg P	Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms.	Blood	2014	71
24740812	3717	Rampal R	Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis.	Blood	2014	55
24986690	3717	Rumi E	Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis.	Blood	2014	32
25037629	3717	Tefferi A	Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis.	Blood	2014	35
25572172	3717	Kleppe M	JAK-STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response.	Cancer discovery	2015	27
25671252	3717	Ortmann CA	Effect of mutation order on myeloproliferative neoplasms.	The New England journal of medicine	2015	55
26332546	3717	Baerlocher GM	Telomerase Inhibitor Imetelstat in Patients with Essential Thrombocythemia.	The New England journal of medicine	2015	16
16843266	3718	Walters DK	Activating alleles of JAK3 in acute megakaryoblastic leukemia.	Cancer cell	2006	89
20400977	3718	Yamashita Y	Array-based genomic resequencing of human leukemia.	Oncogene	2010	69
7479840	3815	Nagata H	Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder.	Proceedings of the National Academy of Sciences of the United States of America	1995	129
16921041	3815	Paschka P	Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study.	Journal of clinical oncology 	2006	105
21399664	3815	Gao XN	MicroRNA-193a represses c-kit expression and functions as a methylation-silenced tumor suppressor in acute myeloid leukemia.	Oncogene	2011	41
19934290	3845	Ogino S	KRAS mutation in stage III colon cancer and clinical outcome following intergroup trial CALGB 89803.	Clinical cancer research 	2009	62
20505728	3845	Lee W	The mutation spectrum revealed by paired genome sequences from a lung cancer patient.	Nature	2010	197
9558396	4170	Kitada S	Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: correlations with In vitro and In vivo chemoresponses.	Blood	1998	111
15637055	4170	Weng C	Specific cleavage of Mcl-1 by caspase-3 in tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in Jurkat leukemia T cells.	The Journal of biological chemistry	2005	66
18599795	4170	Pepper C	Mcl-1 expression has in vitro and in vivo significance in chronic lymphocytic leukemia and is associated with other poor prognostic markers.	Blood	2008	69
20164920	4170	Beroukhim R	The landscape of somatic copy-number alteration across human cancers.	Nature	2010	936
20526282	4170	Harley ME	Phosphorylation of Mcl-1 by CDK1-cyclin B1 initiates its Cdc20-dependent destruction during mitotic arrest.	The EMBO journal	2010	93
21368834	4170	Wertz IE	Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7.	Nature	2011	217
22184378	4170	Roberts AW	Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease.	Journal of clinical oncology 	2012	186
12482972	4297	Hsieh JJ	Proteolytic cleavage of MLL generates a complex of N- and C-terminal fragments that confers protein stability and subnuclear localization.	Molecular and cellular biology	2003	78
15464450	4297	Hess JL	MLL: a histone methyltransferase disrupted in leukemia.	Trends in molecular medicine	2004	96
18538732	4297	Wei J	Microenvironment determines lineage fate in a human model of MLL-AF9 leukemia.	Cancer cell	2008	108
19262598	4297	Meyer C	New insights to the MLL recombinome of acute leukemias.	Leukemia	2009	93
19528532	4297	Balgobind BV	Novel prognostic subgroups in childhood 11q23/MLL-rearranged acute myeloid leukemia: results of an international retrospective study.	Blood	2009	58
20016527	4297	Salzer WL	Long-term results of the pediatric oncology group studies for childhood acute lymphoblastic leukemia 1984-2001: a report from the children's oncology group.	Leukemia	2010	46
22017583	4297	Muntean AG	The pathogenesis of mixed-lineage leukemia.	Annual review of pathology	2012	73
22936661	4297	Shi A	Structural insights into inhibition of the bivalent menin-MLL interaction by small molecules in leukemia.	Blood	2012	36
23628958	4297	Meyer C	The MLL recombinome of acute leukemias in 2013.	Leukemia	2013	81
25730765	4297	Andersson AK	The landscape of somatic mutations in infant MLL-rearranged acute lymphoblastic leukemias.	Nature genetics	2015	46
25998713	4297	Rao RC	Hijacked in cancer: the KMT2 (MLL) family of methyltransferases.	Nature reviews. Cancer	2015	36
26237430	4297	Lavallée VP	The transcriptomic landscape and directed chemical interrogation of MLL-rearranged acute myeloid leukemias.	Nature genetics	2015	16
26331536	4297	Zhu J	Gain-of-function p53 mutants co-opt chromatin pathways to drive cancer growth.	Nature	2015	51
16868251	4352	Pardanani AD	MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients.	Blood	2006	185
17435759	4602	Lahortiga I	Duplication of the MYB oncogene in T cell acute lymphoblastic leukemia.	Nature genetics	2007	75
17452517	4602	Clappier E	The C-MYB locus is involved in chromosomal translocation and genomic duplications in human T-cell acute leukemia (T-ALL), the translocation defining a new T-ALL subtype in very young children.	Blood	2007	84
19841262	4602	Persson M	Recurrent fusion of MYB and NFIB transcription factor genes in carcinomas of the breast and head and neck.	Proceedings of the National Academy of Sciences of the United States of America	2009	125
25394790	4602	Mansour MR	Oncogene regulation. An oncogenic super-enhancer formed through somatic mutation of a noncoding intergenic element.	Science	2014	104
16760443	4609	Dave SS	Molecular diagnosis of Burkitt's lymphoma.	The New England journal of medicine	2006	179
17646408	4609	Thompson BJ	The SCFFBW7 ubiquitin ligase complex as a tumor suppressor in T cell leukemia.	The Journal of experimental medicine	2007	147
21642962	4615	Puente XS	Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia.	Nature	2011	365
1831692	4851	Ellisen LW	TAN-1, the human homolog of the Drosophila notch gene, is broken by chromosomal translocations in T lymphoblastic neoplasms.	Cell	1991	380
15472075	4851	Weng AP	Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia.	Science	2004	749
16738328	4851	Malecki MJ	Leukemia-associated mutations within the NOTCH1 heterodimerization domain fall into at least two distinct mechanistic classes.	Molecular and cellular biology	2006	88
17173050	4851	Vilimas T	Targeting the NF-kappaB signaling pathway in Notch1-induced T-cell leukemia.	Nature medicine	2007	91
17575125	4851	Malyukova A	The tumor suppressor gene hCDC4 is frequently mutated in human T-cell acute lymphoblastic leukemia with functional consequences for Notch signaling.	Cancer research	2007	57
17873882	4851	Palomero T	Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia.	Nature medicine	2007	277
20008221	4851	Ferrando AA	The role of NOTCH1 signaling in T-ALL.	Hematology. American Society of Hematology. Education Program	2009	51
21948802	4851	Lobry C	Oncogenic and tumor suppressor functions of Notch in cancer: it's NOTCH what you think.	The Journal of experimental medicine	2011	94
22006338	4851	Wang NJ	Loss-of-function mutations in Notch receptors in cutaneous and lung squamous cell carcinoma.	Proceedings of the National Academy of Sciences of the United States of America	2011	108
22077063	4851	Rossi D	Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia.	Blood	2012	63
22207691	4851	Del Giudice I	NOTCH1 mutations in +12 chronic lymphocytic leukemia (CLL) confer an unfavorable prognosis, induce a distinctive transcriptional profiling and refine the intermediate prognosis of +12 CLL.	Haematologica	2012	36
23295735	4851	Villamor N	NOTCH1 mutations identify a genetic subgroup of chronic lymphocytic leukemia patients with high risk of transformation and poor outcome.	Leukemia	2013	26
23825651	4851	Kluk MJ	Gauging NOTCH1 Activation in Cancer Using Immunohistochemistry.	PloS one	2013	28
25194570	4851	Herranz D	A NOTCH1-driven MYC enhancer promotes T cell development, transformation and acute lymphoblastic leukemia.	Nature medicine	2014	45
15659725	4869	Falini B	Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype.	The New England journal of medicine	2005	301
16455956	4869	Thiede C	Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML).	Blood	2006	106
18308931	4869	Garzon R	Distinctive microRNA signature of acute myeloid leukemia bearing cytoplasmic mutated nucleophosmin.	Proceedings of the National Academy of Sciences of the United States of America	2008	152
20026798	4869	Becker H	Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B study.	Journal of clinical oncology 	2010	83
21030560	4869	Falini B	Acute myeloid leukemia with mutated nucleophosmin (NPM1): is it a distinct entity?	Blood	2011	40
21555683	4869	Krönke J	Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia: a study from the German-Austrian acute myeloid leukemia study group.	Journal of clinical oncology 	2011	47
22370328	4869	Jerez A	Topography, clinical, and genomic correlates of 5q myeloid malignancies revisited.	Journal of clinical oncology 	2012	33
23634996	4869	Cancer Genome Atlas Research Network.	Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia.	The New England journal of medicine	2013	712
24220271	4869	Dawson MA	Recurrent mutations, including NPM1c, activate a BRD4-dependent core transcriptional program in acute myeloid leukemia.	Leukemia	2014	29
26789727	4869	Ivey A	Assessment of Minimal Residual Disease in Standard-Risk AML.	The New England journal of medicine	2016	31
23406027	4893	Ho AL	Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer.	The New England journal of medicine	2013	83
17589499	4928	Wang GG	NUP98-NSD1 links H3K36 methylation to Hox-A gene activation and leukaemogenesis.	Nature cell biology	2007	105
21948299	4928	Gough SM	NUP98 gene fusions and hematopoietic malignancies: common themes and new biologic insights.	Blood	2011	53
17344859	5079	Mullighan CG	Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia.	Nature	2007	467
1652368	5371	Kakizuka A	Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RAR alpha with a novel putative transcription factor, PML.	Cell	1991	267
1652369	5371	de Thé H	The PML-RAR alpha fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR.	Cell	1991	256
8131741	5371	Koken MH	The t(15;17) translocation alters a nuclear body in a retinoic acid-reversible fashion.	The EMBO journal	1994	120
8293468	5371	Weis K	Retinoic acid regulates aberrant nuclear localization of PML-RAR alpha in acute promyelocytic leukemia cells.	Cell	1994	163
14970276	5371	Gurrieri C	Loss of the tumor suppressor PML in human cancers of multiple histologic origins.	Journal of the National Cancer Institute	2004	93
18160441	5371	Everett RD	Replication of ICP0-null mutant herpes simplex virus type 1 is restricted by both PML and Sp100.	Journal of virology	2008	99
20378816	5371	Zhang XW	Arsenic trioxide controls the fate of the PML-RARalpha oncoprotein by directly binding PML.	Science	2010	152
12826400	5781	Neel BG	The 'Shp'ing news: SH2 domain-containing tyrosine phosphatases in cell signaling.	Trends in biochemical sciences	2003	301
14644997	5781	Loh ML	Mutations in PTPN11 implicate the SHP-2 phosphatase in leukemogenesis.	Blood	2004	92
15604238	5781	Bentires-Alj M	Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia.	Cancer research	2004	127
16358218	5781	Tartaglia M	Diversity and functional consequences of germline and somatic PTPN11 mutations in human disease.	American journal of human genetics	2006	88
17143285	5781	Roberts AE	Germline gain-of-function mutations in SOS1 cause Noonan syndrome.	Nature genetics	2007	125
18286234	5781	Chan G	The tyrosine phosphatase Shp2 (PTPN11) in cancer.	Cancer metastasis reviews	2008	111
20399956	5781	Grossmann KS	The tyrosine phosphatase Shp2 in development and cancer.	Advances in cancer research	2010	50
2170850	5914	de Thé H	The t(15;17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor alpha gene to a novel transcribed locus.	Nature	1990	171
2673546	5925	Chen PL	Phosphorylation of the retinoblastoma gene product is modulated during the cell cycle and cellular differentiation.	Cell	1989	215
22529291	5925	Egan JB	Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides.	Blood	2012	85
22389253	6427	Thol F	Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes.	Blood	2012	82
22431577	6427	Zhang SJ	Genetic analysis of patients with leukemic transformation of myeloproliferative neoplasms shows recurrent SRSF2 mutations that are associated with adverse outcome.	Blood	2012	36
22919025	6427	Meggendorfer M	SRSF2 mutations in 275 cases with chronic myelomonocytic leukemia (CMML).	Blood	2012	45
26261309	6427	Zhang J	Disease-associated mutation in SRSF2 misregulates splicing by altering RNA-binding affinities.	Proceedings of the National Academy of Sciences of the United States of America	2015	20
22591296	6774	Koskela HL	Somatic STAT3 mutations in large granular lymphocytic leukemia.	The New England journal of medicine	2012	125
22859607	6774	Jerez A	STAT3 mutations unify the pathogenesis of chronic lymphoproliferative disorders of NK cells and T-cell large granular lymphocyte leukemia.	Blood	2012	71
15685439	7157	Ohgaki H	Epidemiology and etiology of gliomas.	Acta neuropathologica	2005	212
17468756	7157	Theodorou V	MMTV insertional mutagenesis identifies genes, gene families and pathways involved in mammary cancer.	Nature genetics	2007	69
18689542	7157	Zenz T	Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up.	Blood	2008	76
19188171	7157	Rossi D	The prognostic value of TP53 mutations in chronic lymphocytic leukemia is independent of Del17p13: implications for overall survival and chemorefractoriness.	Clinical cancer research 	2009	48
20538793	7157	Lin TT	Telomere dysfunction and fusion during the progression of chronic lymphocytic leukemia: evidence for a telomere crisis.	Blood	2010	42
20697090	7157	Zenz T	TP53 mutation and survival in chronic lymphocytic leukemia.	Journal of clinical oncology 	2010	91
21205967	7157	Fabbri M	Association of a microRNA/TP53 feedback circuitry with pathogenesis and outcome of B-cell chronic lymphocytic leukemia.	JAMA	2011	72
21483000	7157	Gonzalez D	Mutational status of the TP53 gene as a predictor of response and survival in patients with chronic lymphocytic leukemia: results from the LRF CLL4 trial.	Journal of clinical oncology 	2011	47
21519010	7157	Jädersten M	TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression.	Journal of clinical oncology 	2011	69
21747090	7157	Hof J	Mutations and deletions of the TP53 gene predict nonresponse to treatment and poor outcome in first relapse of childhood acute lymphoblastic leukemia.	Journal of clinical oncology 	2011	41
22186996	7157	Rücker FG	TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome.	Blood	2012	69
22265402	7157	Rausch T	Genome sequencing of pediatric medulloblastoma links catastrophic DNA rearrangements with TP53 mutations.	Cell	2012	175
22297721	7157	Pospisilova S	ERIC recommendations on TP53 mutation analysis in chronic lymphocytic leukemia.	Leukemia	2012	38
22965953	7157	Lehmann S	Targeting p53 in vivo: a first-in-human study with p53-targeting compound APR-246 in refractory hematologic malignancies and prostate cancer.	Journal of clinical oncology 	2012	58
23297687	7157	Kulasekararaj AG	TP53 mutations in myelodysplastic syndrome are strongly correlated with aberrations of chromosome 5, and correlate with adverse prognosis.	British journal of haematology	2013	44
24501221	7157	Rossi D	Clinical impact of small TP53 mutated subclones in chronic lymphocytic leukemia.	Blood	2014	50
24682512	7157	Saft L	p53 protein expression independently predicts outcome in patients with lower-risk myelodysplastic syndromes with del(5q).	Haematologica	2014	22
25287991	7157	Malcikova J	Detailed analysis of therapy-driven clonal evolution of TP53 mutations in chronic lymphocytic leukemia.	Leukemia	2015	18
25555420	7157	Farooqui MZ	Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial.	The Lancet. Oncology	2015	51
12595313	7535	Wiestner A	ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile.	Blood	2003	100
15284443	7535	Calin GA	MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias.	Proceedings of the National Academy of Sciences of the United States of America	2004	348
17008705	7535	Shanafelt TD	Prospective evaluation of clonal evolution during long-term follow-up of patients with untreated early-stage chronic lymphocytic leukemia.	Journal of clinical oncology 	2006	62
18577710	7535	Rassenti LZ	Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia.	Blood	2008	86
17178851	8115	Pekarsky Y	Tcl1 expression in chronic lymphocytic leukemia is regulated by miR-29 and miR-181.	Cancer research	2006	195
20724988	10019	Pardanani A	LNK mutation studies in blast-phase myeloproliferative neoplasms, and in chronic-phase disease with TET2, IDH, JAK2 or MPL mutations.	Leukemia	2010	42
22897847	10019	Roberts KG	Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia.	Cancer cell	2012	141
24056718	10019	Yoshida K	The landscape of somatic mutations in Down syndrome-related myeloid disorders.	Nature genetics	2013	41
25207766	10019	Roberts KG	Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia.	The New England journal of medicine	2014	142
16522815	10153	Cancer and Leukemia Group B 8461.	Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461.	Blood	2006	62
20425795	10153	Cammarata G	Differential expression of specific microRNA and their targets in acute myeloid leukemia.	American journal of hematology	2010	48
22875911	10153	Yin JA	Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trial.	Blood	2012	48
18768390	10320	Yang JJ	Genome-wide copy number profiling reveals molecular evolution from diagnosis to relapse in childhood acute lymphoblastic leukemia.	Blood	2008	55
19129520	10320	Mullighan CG	Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia.	The New England journal of medicine	2009	274
19589926	10320	Iacobucci I	Identification and molecular characterization of recurrent genomic deletions on 7p12 in the IKZF1 gene in a large cohort of BCR-ABL1-positive acute lymphoblastic leukemia patients: on behalf of Gruppo Italiano Malattie Ematologiche dell'Adulto Acute Leukemia Working Party (GIMEMA AL WP).	Blood	2009	50
19770381	10320	Martinelli G	IKZF1 (Ikaros) deletions in BCR-ABL1-positive acute lymphoblastic leukemia are associated with short disease-free survival and high rate of cumulative incidence of relapse: a GIMEMA AL WP report.	Journal of clinical oncology 	2009	61
20139093	10320	Harvey RC	Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia.	Blood	2010	112
20445578	10320	Kuiper RP	IKZF1 deletions predict relapse in uniformly treated pediatric precursor B-ALL.	Leukemia	2010	57
21531982	10320	Klampfl T	Genome integrity of myeloproliferative neoplasms in chronic phase and during disease progression.	Blood	2011	36
22368272	10320	Chen IM	Outcome modeling with CRLF2, IKZF1, JAK, and minimal residual disease in pediatric acute lymphoblastic leukemia: a Children's Oncology Group study.	Blood	2012	59
23212523	10320	Loh ML	Tyrosine kinome sequencing of pediatric acute lymphoblastic leukemia: a report from the Children's Oncology Group TARGET Project.	Blood	2013	32
24366361	10320	van der Veer A	IKZF1 status as a prognostic feature in BCR-ABL1-positive childhood ALL.	Blood	2014	25
24740809	10320	Beldjord K	Oncogenetics and minimal residual disease are independent outcome predictors in adult patients with acute lymphoblastic leukemia.	Blood	2014	23
26321221	10320	Churchman ML	Efficacy of Retinoids in IKZF1-Mutated BCR-ABL1 Acute Lymphoblastic Leukemia.	Cancer cell	2015	19
23955599	10735	Kon A	Recurrent mutations in multiple components of the cohesin complex in myeloid neoplasms.	Nature genetics	2013	71
24136165	10735	Cazzola M	The genetic basis of myelodysplasia and its clinical relevance.	Blood	2013	59
25006131	10735	Thota S	Genetic alterations of the cohesin complex genes in myeloid malignancies.	Blood	2014	28
25550361	10735	Lindsley RC	Acute myeloid leukemia ontogeny is defined by distinct somatic mutations.	Blood	2015	51
26466571	22806	Landau DA	Mutations driving CLL and their evolution in progression and relapse.	Nature	2015	72
23134356	22882	Callahan MK	Progression of RAS-mutant leukemia during RAF inhibitor treatment.	The New England journal of medicine	2012	57
24178622	22882	Jain N	Phase II study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: a University of Chicago phase II consortium trial.	Clinical cancer research 	2014	27
25324352	22882	Hyman DM	Prospective blinded study of BRAFV600E mutation detection in cell-free DNA of patients with systemic histiocytic disorders.	Cancer discovery	2015	27
26566875	22882	Diamond EL	Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms.	Cancer discovery	2016	21
21909114	23451	Yoshida K	Frequent pathway mutations of splicing machinery in myelodysplasia.	Nature	2011	365
21998214	23451	Malcovati L	Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms.	Blood	2011	91
22096241	23451	Patnaik MM	SF3B1 mutations are prevalent in myelodysplastic syndromes with ring sideroblasts but do not hold independent prognostic value.	Blood	2012	38
22323480	23451	Makishima H	Mutations in the spliceosome machinery, a novel and ubiquitous pathway in leukemogenesis.	Blood	2012	111
23086750	23451	Oscier DG	The clinical significance of NOTCH1 and SF3B1 mutations in the UK LRF CLL4 trial.	Blood	2013	51
23160465	23451	Cazzola M	Biologic and clinical significance of somatic mutations of SF3B1 in myeloid and lymphoid neoplasms.	Blood	2013	25
23415222	23451	Landau DA	Evolution and impact of subclonal mutations in chronic lymphocytic leukemia.	Cell	2013	299
24113472	23451	Jeromin S	SF3B1 mutations correlated to cytogenetics and mutations in NOTCH1, FBXW7, MYD88, XPO1 and TP53 in 1160 untreated CLL patients.	Leukemia	2014	37
24652989	23451	Stilgenbauer S	Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial.	Blood	2014	49
24943832	23451	Baliakas P	Recurrent mutations refine prognosis in chronic lymphocytic leukemia.	Leukemia	2015	46
24970933	23451	Malcovati L	Driver somatic mutations identify distinct disease entities within myeloid neoplasms with myelodysplasia.	Blood	2014	27
26565915	23451	Darman RB	Cancer-Associated SF3B1 Hotspot Mutations Induce Cryptic 3' Splice Site Selection through Use of a Different Branch Point.	Cell reports	2015	34
26675346	23451	Ljungström V	Whole-exome sequencing in relapsing chronic lymphocytic leukemia: clinical impact of recurrent RPS15 mutations.	Blood	2016	12
26837699	23451	Nadeu F	Clinical impact of clonal and subclonal TP53, SF3B1, BIRC3, NOTCH1, and ATM mutations in chronic lymphocytic leukemia.	Blood	2016	15
23443343	26040	Damm F	SETBP1 mutations in 658 patients with myelodysplastic syndromes, chronic myelomonocytic leukemia and secondary acute myeloid leukemias.	Leukemia	2013	29
23558523	26040	Laborde RR	SETBP1 mutations in 415 patients with primary myelofibrosis or chronic myelomonocytic leukemia: independent prognostic impact in CMML.	Leukemia	2013	27
23604229	26040	Pardanani A	CSF3R T618I is a highly prevalent and specific mutation in chronic neutrophilic leukemia.	Leukemia	2013	39
23628959	26040	Meggendorfer M	SETBP1 mutations occur in 9% of MDS/MPN and in 4% of MPN cases and are strongly associated with atypical CML, monosomy 7, isochromosome i(17)(q10), ASXL1 and CBL mutations.	Leukemia	2013	27
22366949	30012	Della Gatta G	Reverse engineering of TLX oncogenic transcriptional networks identifies RUNX1 as tumor suppressor in T-ALL.	Nature medicine	2012	45
20660823	54474	Thomas DA	Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia.	Journal of clinical oncology 	2010	47
23720127	54474	Hallek M	Chronic lymphocytic leukemia: 2013 update on diagnosis, risk stratification and treatment.	American journal of hematology	2013	37
25049322	54474	Byrd JC	Entering the era of targeted therapy for chronic lymphocytic leukemia: impact on the practicing clinician.	Journal of clinical oncology 	2014	35
25908509	54474	Hallek M	Chronic lymphocytic leukemia: 2015 Update on diagnosis, risk stratification, and treatment.	American journal of hematology	2015	38
19262599	54790	Tefferi A	Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates.	Leukemia	2009	55
19262601	54790	Tefferi A	TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis.	Leukemia	2009	96
19372255	54790	Jankowska AM	Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/myeloproliferative neoplasms.	Blood	2009	104
19666869	54790	Kosmider O	TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs).	Blood	2009	59
19797729	54790	Kosmider O	TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia.	Haematologica	2009	49
20644105	54790	Kohlmann A	Next-generation sequencing technology reveals a characteristic pattern of molecular mutations in 72.8% of chronic myelomonocytic leukemia by detecting frequent alterations in TET2, CBL, RAS, and RUNX1.	Journal of clinical oncology 	2010	65
20693430	54790	Smith AE	Next-generation sequencing of the TET2 gene in 355 MDS and CMML patients reveals low-abundance mutant clones with early origins, but indicates no definite prognostic value.	Blood	2010	53
21343549	54790	Metzeler KH	TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study.	Journal of clinical oncology 	2011	86
21494260	54790	Itzykson R	Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias.	Leukemia	2011	82
21734233	54790	Pronier E	Inhibition of TET2-mediated conversion of 5-methylcytosine to 5-hydroxymethylcytosine disturbs erythroid and granulomonocytic differentiation of human hematopoietic progenitors.	Blood	2011	47
21828143	54790	Chou WC	TET2 mutation is an unfavorable prognostic factor in acute myeloid leukemia patients with intermediate-risk cytogenetics.	Blood	2011	50
22116554	54790	Weissmann S	Landscape of TET2 mutations in acute myeloid leukemia.	Leukemia	2012	41
22430270	54790	Gaidzik VI	TET2 mutations in acute myeloid leukemia (AML): results from a comprehensive genetic and clinical analysis of the AML study group.	Journal of clinical oncology 	2012	43
23319568	54790	Itzykson R	Clonal architecture of chronic myelomonocytic leukemias.	Blood	2013	40
23359070	54790	Lobry C	Notch pathway activation targets AML-initiating cell homeostasis and differentiation.	The Journal of experimental medicine	2013	38
24373966	54790	Madzo J	Hydroxymethylation at gene regulatory regions directs stem/early progenitor cell commitment during erythropoiesis.	Cell reports	2014	25
12809610	60489	Harris RS	DNA deamination mediates innate immunity to retroviral infection.	Cell	2003	551
19641190	64109	Russell LJ	Deregulated expression of cytokine receptor gene, CRLF2, is involved in lymphoid transformation in B-cell precursor acute lymphoblastic leukemia.	Blood	2009	105
19838194	64109	Mullighan CG	Rearrangement of CRLF2 in B-progenitor- and Down syndrome-associated acute lymphoblastic leukemia.	Nature genetics	2009	140
18497858	85363	Rold CJ	Proteasomal degradation of TRIM5alpha during retrovirus restriction.	PLoS pathogens	2008	60
21483490	85363	Ohkura S	Novel escape mutants suggest an extensive TRIM5α binding site spanning the entire outer surface of the murine leukemia virus capsid protein.	PLoS pathogens	2011	35
22114335	85363	Roa A	RING domain mutations uncouple TRIM5α restriction of HIV-1 from inhibition of reverse transcription and acceleration of uncoating.	Journal of virology	2012	37
19388938	171023	Gelsi-Boyer V	Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia.	British journal of haematology	2009	137
20068184	171023	Abdel-Wahab O	Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias.	Cancer research	2010	68
20693432	171023	Chou WC	Distinct clinical and biological features of de novo acute myeloid leukemia with additional sex comb-like 1 (ASXL1) mutations.	Blood	2010	41
20880116	171023	Gelsi-Boyer V	ASXL1 mutation is associated with poor prognosis and acute transformation in chronic myelomonocytic leukaemia.	British journal of haematology	2010	46
21576631	171023	Thol F	Prognostic significance of ASXL1 mutations in patients with myelodysplastic syndromes.	Journal of clinical oncology 	2011	59
21714648	171023	Bejar R	Clinical effect of point mutations in myelodysplastic syndromes.	The New England journal of medicine	2011	261
22031865	171023	Metzeler KH	ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category.	Blood	2011	61
22343920	171023	Damm F	Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes.	Blood	2012	47
22489043	171023	Brecqueville M	Mutation analysis of ASXL1, CBL, DNMT3A, IDH1, IDH2, JAK2, MPL, NF1, SF3B1, SUZ12, and TET2 in myeloproliferative neoplasms.	Genes, chromosomes and cancer	2012	39
22897849	171023	Abdel-Wahab O	ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression.	Cancer cell	2012	95
22898539	171023	Shih AH	The role of mutations in epigenetic regulators in myeloid malignancies.	Nature reviews. Cancer	2012	186
22915647	171023	Grossmann V	A novel hierarchical prognostic model of AML solely based on molecular mutations.	Blood	2012	37
23018865	171023	Schnittger S	ASXL1 exon 12 mutations are frequent in AML with intermediate risk karyotype and are independently associated with an adverse outcome.	Leukemia	2013	38
23349007	171023	Tefferi A	Primary myelofibrosis: 2013 update on diagnosis, risk-stratification, and management.	American journal of hematology	2013	27
23619563	171023	Vannucchi AM	Mutations and prognosis in primary myelofibrosis.	Leukemia	2013	79
23640996	171023	Abdel-Wahab O	Mutations in epigenetic modifiers in the pathogenesis and therapy of acute myeloid leukemia.	Blood	2013	42
23690417	171023	Itzykson R	Prognostic score including gene mutations in chronic myelomonocytic leukemia.	Journal of clinical oncology 	2013	70
23958953	171023	Schwaab J	Comprehensive mutational profiling in advanced systemic mastocytosis.	Blood	2013	28
24045501	171023	Traina F	Impact of molecular mutations on treatment response to DNMT inhibitors in myelodysplasia and related neoplasms.	Leukemia	2014	46
24077845	171023	West RR	Acquired ASXL1 mutations are common in patients with inherited GATA2 mutations and correlate with myeloid transformation.	Haematologica	2014	21
24496303	171023	Tefferi A	CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: an international study of 570 patients.	Leukemia	2014	34
24549259	171023	Guglielmelli P	The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients.	Leukemia	2014	23
24695057	171023	Patnaik MM	ASXL1 and SETBP1 mutations and their prognostic contribution in chronic myelomonocytic leukemia: a two-center study of 466 patients.	Leukemia	2014	25
25224413	171023	Bejar R	TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients.	Blood	2014	56
25326804	171023	Xie M	Age-related mutations associated with clonal hematopoietic expansion and malignancies.	Nature medicine	2014	168
25426838	171023	Genovese G	Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence.	The New England journal of medicine	2014	202
25574665	171023	Gerstung M	Combining gene mutation with gene expression data improves outcome prediction in myelodysplastic syndromes.	Nature communications	2015	21
26132940	171023	Yoshizato T	Somatic Mutations and Clonal Hematopoiesis in Aplastic Anemia.	The New England journal of medicine	2015	30
26182311	171023	Tefferi A	Myeloproliferative Neoplasms: A Contemporary Review.	JAMA oncology	2015	21
14973191	220972	Calin GA	Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers.	Proceedings of the National Academy of Sciences of the United States of America	2004	1066
